Robert J. Chilton, DO
John R. Nelson, MD, FACC, FNLA, FASNC
Clinicians' Update on Omega-3s in ASCVD Risk Reduction
Ileana L. Piña, MD, MPH, FAHA, FACC
Javed Butler, MD, MBA, MPH
Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
From Guidelines to Practice: Key Updates From 2021 HFSA
Gregg C. Fonarow, MD
Demystifying Continued Pharmacologic Therapy in HFrEF – Pivotal Opportunities to Improve Patient Outcomes
Demystifying Continued Pharmacologic Therapy in HFrEF – Pivotal Opportunities...
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
A New Normal? COVID-19 and HF in Clinical Trials
Robert J. Mentz, MD, FHFSA, FACC, FAHA
Peter van der Meer, MD, PhD
A Clinical Guide to the Role of Iron in HF Pathophysiology
George L. Bakris, MD
Rajiv Agarwal, MBBS, MD, FASN, BRCU
Bertram Pit, MD
FIGARO-DKD and FIDELITY Analysis: Key Takeaways
Optimizing RAASi Therapy in Patients with Hyperkalemia: The Role of Potassium Binders
Optimizing RAASi Therapy in Patients with Hyperkalemia: The Role of Potassium...
Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP
Robert Toto, MD
Elevated Creatinine and AKI Are NOT Synonymous: Optimal RAASi Therapy Is Always the Goal
Elevated Creatinine and AKI Are NOT Synonymous: Optimal RAASi Therapy Is Alwa...
Joseph Saseen, PharmD, BCPS, BCACP, CLS
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Variable Effects of Omega-3 Fatty Acids for ASCVD Event Reduction: Why?
Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Leslie Cho, MD
Clinician’s Update on Omega-3s in ASCVD Risk Reduction
Biff F. Palmer, MD
RAASi Therapy, Diabetes, and Hyperkalemia: Halting Therapy Is NOT the Only Option
RAASi Therapy, Diabetes, and Hyperkalemia: Halting Therapy Is NOT the Only Op...
Paul W. Armstrong, MD
Justin Ezekowitz, MD, MBBCh, MSc
Emerging Data on New Therapy Combinations for HFrEF: Raising Clinician Awareness
Potassium Binders Facilitate Continued RAASi Therapy: Helpful Tips for Clinicians
Potassium Binders Facilitate Continued RAASi Therapy: Helpful Tips for Clinic...
Michael Miller, MD, FACC, FAHA, FNLA
Brian Olshansky, MD, FACCP, FAHA, FHRS, FESC
Understanding the Differences Between STRENGTH and REDUCE-IT Omega-3 Fatty Acid Clinical Trials and EPA/DHA
Understanding the Differences Between STRENGTH and REDUCE-IT Omega-3 Fatty Ac...
James A. Underberg, MD
Nathan D. Wong, PhD, MPH
Should EPA Be Another 'E' in the ABCs of CVD Risk Prevention? Straight Talk from the Experts
Should EPA Be Another 'E' in the ABCs of CVD Risk Prevention? Straight Talk f...
New Therapies Offer Improved Outcomes in HFrEF Management
